cagrisema semaglutide cagrilintide phase 3 results 2024 2025 Novo Nordisk's next-gen obesity drug Cagrisema: investors seek answers cagrisema semaglutide cagrilintide phase 3

While it may be useful as a short-term laxative, it is not ideal for long-term magnesium repletion

If you are experiencing unpleasant side effects or suboptimal results from Zepbound, or if your insurance recently stopped covering Zepbound, you might wonder if its possible to switch to Wegovy

The results of the Evaluation of LIXisenatide in Acute coronary syndrome (ELIXA) trial, the first cardiovascular outcomes trial for the short-acting GLP-1 RA lixisenatide, were also published recently [52]

Landmark studies in patients with T2DM including Veteran Affairs Diabetes trial (VADT), the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR controlled Evaluation (ADVANCE) trial, and the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial have provided consistent evidence that intensive glycemic control is the path to follow